Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Ensz

Family Medicine South Sioux City, NE Medical Doctor

NPI 1124245899 CMS profile 51176

501 1St Ave, South Sioux City, NE 68776

Open in the dashboard

General payments

$3,851

241 records reported · program years 2019–2025

Research payments

$587

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,253,695 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Ensz of South Sioux City, NE is reported in the CMS Open Payments database as having received $3,851 across 241 general payments and $587 in research payments paid to them. Separately, studies naming them as principal investigator received $33,253,695 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52 3
2024 General $120 7
2023 General $15 1
2022 General $897 59
2021 General $527 33
2021 Research $587 1
2020 General $1,099 75
2019 General $1,141 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Ensz
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to David Ensz were reported at $52. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year David Ensz Family Medicine median Middle half National median
2019 $1,141 $150 $41–$543 $163
2020 $1,099 $120 $32–$415 $114
2021 $527 $137 $35–$551 $132
2022 $897 $137 $37–$512 $149
2023 $15 $149 $42–$545 $160
2024 $120 $156 $44–$560 $164
2025 $52 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $598 43 payments
  2. AstraZeneca Pharmaceuticals LP $461 15 payments
  3. Amgen Inc. $377 26 payments
  4. AbbVie, Inc. $368 26 payments
  5. Genzyme Corporation $260 3 payments
  6. Allergan Inc. $176 20 payments
  7. Sanofi-Aventis U.S. LLC $174 12 payments
  8. Amarin Pharma Inc. $156 10 payments
  9. Astellas Pharma US Inc $147 4 payments
  10. Pfizer Inc. $133 13 payments
  11. Other $1,000 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,462 235 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $245 2 payments
  3. Education $123 3 payments
  4. Gift $20 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $366 26 payments
  2. FARXIGA $335 9 payments
  3. Repatha $252 18 payments
  4. RYBELSUS $239 17 payments
  5. TOUJEO $225 4 payments
  6. Otezla $187 13 payments
  7. VRAYLAR $159 11 payments
  8. Vascepa $156 10 payments
  9. NURTEC ODT $152 11 payments
  10. SYMBICORT $135 4 payments
  11. Other $2,724 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biohaven Pharmaceuticals, Inc. $587 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 192 drugs

Part D claims

13,347

Median for Family Practice: 1,826

Drug cost

$1,201,538

Median for Family Practice: $120,094

Branded share of claims

21.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 249 $168,886
Ozempic Semaglutide Brand 103 $119,752
Farxiga Dapagliflozin Propanediol Brand 95 $87,543
Trulicity Dulaglutide Brand 45 $74,817
Mounjaro Tirzepatide Brand 54 $72,199
Tresiba Flextouch U-200 Insulin Degludec Brand 59 $46,956
Rybelsus Semaglutide Brand 33 $43,768
Linzess Linaclotide Brand 31 $30,309
Entresto Sacubitril/Valsartan Brand 70 $30,176
Myrbetriq Mirabegron Brand 64 $29,870

The 10 drugs with the highest cost, of 192 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$154,940

Of which drugs: $13,027

Medicare patients

398

Average age 73

Services billed

4,331

200 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 32%
Diabetes 31%
Ischemic heart disease 24%
Chronic kidney disease 24%
Depression 22%
Heart failure 19%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 24 24 $6,992
Vaccine for influenza for injection into muscle 90653 Office 71 71 $5,260
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 284 $215
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 65 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $44
$44 — —
Otezla
  • Amgen Inc. $31
$31 — —
Repatha
  • Amgen Inc. $31
$31 45 —
LINZESS
  • AbbVie, Inc. $7
$7 31 —
VIBERZI
  • AbbVie, Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record